141 related articles for article (PubMed ID: 14751508)
1. In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2'-deoxyuridine activated by hypoxic irradiation.
Shibamoto Y; Tachi Y; Tanabe K; Hatta H; Nishimoto S
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):397-402. PubMed ID: 14751508
[TBL] [Abstract][Full Text] [Related]
2. A novel class of antitumor prodrug, 1-(2'-oxopropyl)-5-fluorouracil (OFU001), that releases 5-fluorouracil upon hypoxic irradiation.
Shibamoto Y; Zhou L; Hatta H; Mori M; Nishimoto S
Jpn J Cancer Res; 2000 Apr; 91(4):433-8. PubMed ID: 10804292
[TBL] [Abstract][Full Text] [Related]
3. In vivo evaluation of a novel antitumor prodrug, 1-(2'-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation.
Shibamoto Y; Zhou L; Hatta H; Mori M; Nishimoto SI
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):407-13. PubMed ID: 11173134
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 5-fluorouracil and 5-fluoro-2'-deoxyuridine as an effector in radiation-activated prodrugs.
Shibamoto Y; Mimasu Y; Tachi Y; Hatta H; Nishimoto S
J Chemother; 2002 Aug; 14(4):390-6. PubMed ID: 12420858
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-selective activation of 5-fluorodeoxyuridine prodrug possessing indolequinone structure: radiolytic reduction and cytotoxicity characteristics.
Tanabe K; Makimura Y; Tachi Y; Imagawa-Sato A; Nishimoto S
Bioorg Med Chem Lett; 2005 May; 15(9):2321-4. PubMed ID: 15837317
[TBL] [Abstract][Full Text] [Related]
6. Reductive activation of 5-fluorodeoxyuridine prodrug possessing azide methyl group by hypoxic X-irradiation.
Tanabe K; Ishizaki J; Ando Y; Ito T; Nishimoto S
Bioorg Med Chem Lett; 2012 Feb; 22(4):1682-5. PubMed ID: 22248856
[TBL] [Abstract][Full Text] [Related]
7. One-electron reduction characteristics of N(3)-substituted 5-fluorodeoxyuridines synthesized as radiation-activated prodrugs.
Tanabe K; Mimasu Y; Eto A; Tachi Y; Sakakibara S; Mori M; Hatta H; Nishimoto S
Bioorg Med Chem; 2003 Oct; 11(21):4551-6. PubMed ID: 14527551
[TBL] [Abstract][Full Text] [Related]
8. The Japanese experiences with hypoxia-targeting pharmacoradiotherapy: from hypoxic cell sensitisers to radiation-activated prodrugs.
Shibamoto Y; Sugie C; Ito M; Ogino H
Expert Opin Pharmacother; 2004 Dec; 5(12):2459-67. PubMed ID: 15571464
[TBL] [Abstract][Full Text] [Related]
9. A new class of 5-fluoro-2'-deoxyuridine prodrugs conjugated with a tumor-homing cyclic peptide CNGRC by ester linkers: synthesis, reactivity, and tumor-cell-selective cytotoxicity.
Zhang Z; Hatta H; Tanabe K; Nishimoto S
Pharm Res; 2005 Mar; 22(3):381-9. PubMed ID: 15835743
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of 5-fluoro-2'-deoxyuridine antitumor efficacy by the uridine phosphorylase inhibitor 5-(benzyloxybenzyl)barbituric acid acyclonucleoside.
Ashour OM; Naguib FN; Khalifa MM; Abdel-Raheem MH; Panzica RP; el Kouni MH
Cancer Res; 1995 Mar; 55(5):1092-8. PubMed ID: 7866994
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2,2-trichloroethyl)phosphate derivatives of 5-fluoro-2'-deoxyuridine and 2',5-difluoro-2'-deoxyuridine as potential dual action anticancer prodrugs.
Xia Z; Wiebe LI; Miller GG; Knaus EE
Arch Pharm (Weinheim); 1999 Aug; 332(8):286-94. PubMed ID: 10489539
[TBL] [Abstract][Full Text] [Related]
12. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
13. Stereoelectronic effect on one-electron reductive release of 5-fluorouracil from 5-fluoro-1-(2-oxocycloalkyl)uracils as a new class of radiation-activated antitumor prodrugs.
Mori M; Hatta H; Nishimoto S
J Org Chem; 2000 Jul; 65(15):4641-7. PubMed ID: 10959869
[TBL] [Abstract][Full Text] [Related]
14. Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator.
Ahn GO; Botting KJ; Patterson AV; Ware DC; Tercel M; Wilson WR
Biochem Pharmacol; 2006 Jun; 71(12):1683-94. PubMed ID: 16620789
[TBL] [Abstract][Full Text] [Related]
15. Effect of administration of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on the anti-tumor efficacy of 5-fluoro-2'-deoxyuridine against murine colon tumor C26-10.
Ashour OM; Naguib FN; Goudgaon NM; Schinazi RF; el Kouni MH
Biochem Pharmacol; 2000 Sep; 60(5):687-92. PubMed ID: 10927027
[TBL] [Abstract][Full Text] [Related]
16. Role of fluoropyrimidine Schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma.
Cao S; Frank C; Rustum YM
J Natl Cancer Inst; 1996 Apr; 88(7):430-6. PubMed ID: 8618234
[TBL] [Abstract][Full Text] [Related]
17. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
Fukushima M; Sakamoto K; Sakata M; Nakagawa F; Saito H; Sakata Y
Oncol Rep; 2010 Nov; 24(5):1307-13. PubMed ID: 20878125
[TBL] [Abstract][Full Text] [Related]
18. Radiolytic activation of a cytarabine prodrug possessing a 2-oxoalkyl group: one-electron reduction and cytotoxicity characteristics.
Hirata N; Fujisawa Y; Tanabe K; Harada H; Hiraoka M; Nishimoto S
Org Biomol Chem; 2009 Feb; 7(4):651-4. PubMed ID: 19194578
[TBL] [Abstract][Full Text] [Related]
19. The achievement of mass balance by simultaneous quantification of floxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, α-fluoro-β-ureidopropionate, α-fluoro-β-alanine using LC-MS.
Tsume Y; Provoda CJ; Amidon GL
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Apr; 879(13-14):915-20. PubMed ID: 21450537
[TBL] [Abstract][Full Text] [Related]
20. Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts.
Wilson WR; Tercel M; Anderson RF; Denny WA
Anticancer Drug Des; 1998 Sep; 13(6):663-85. PubMed ID: 9755724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
